Treatment of Multifood Allergy With Omalizumab or Multiallergen Oral Immunotherapy

How do omalizumab and oral immunotherapy (OIT) compare in the treatment of patients with multifood allergy? In this randomized clinical trial comparing omalizumab with multiallergen OIT (MOIT) in 117 participants with multifood allergy, omalizumab was superior in terms of both efficacy and safety. Although the intention-to-treat analysis found a higher rate of treatment success in those receiving omalizumab, there was no difference in efficacy after accounting for the high rate of study withdrawals in the group of participants treated with omalizumab-facilitated MOIT.

Corresponding Author: Robert A. Wood, MD, Department of Pediatrics, Johns Hopkins University, 600 N Wolfe St, Blalock 452, Baltimore, MD 21287 (rwood@jhmi.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.